Early trial launches for aggressive prostate cancer combo
NCT ID NCT06866548
Summary
This early-stage trial is testing the safety and initial effectiveness of combining two antibody drugs for men with metastatic castration-resistant prostate cancer (mCRPC). The study involves a very small group of 7 participants to see if the drug combination is safe and if it can help control the cancer. The main goal is to find a safe dose and see if the treatment can slow cancer growth or improve quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRPC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.